(Q34758160)

4 August 2017

1 reference

title

Dutasteride: a review of its use in the management of prostate disorders (English)

1 reference

4 August 2017

1 reference

2

Lesley J Scott

1 reference

4 August 2017

Susan J Keam

1

1 reference

4 August 2017

publication date

1 January 2008

1 reference

4 August 2017

1 reference

4 August 2017

volume

68

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

463-485

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200868040-00008

4 August 2017

exact match

0 references

cites work

Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200868040-00008

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

21 January 2018

1 reference

12 December 2020

The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response

1 reference

12 December 2020

Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia

1 reference

12 December 2020

The relative impact and future burden of prostate cancer in the United States.

1 reference

12 December 2020

Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician

1 reference

12 December 2020

UROLOGIC DISEASES IN AMERICA PROJECT: BENIGN PROSTATIC HYPERPLASIA

1 reference

12 December 2020

5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery

1 reference

12 December 2020

Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations

1 reference

12 December 2020

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer

1 reference

12 December 2020

Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater

1 reference

12 December 2020

Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer

1 reference

12 December 2020

Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer

1 reference

12 December 2020

Optimising the medical management of benign prostatic hyperplasia

1 reference

12 December 2020

Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia

1 reference

12 December 2020

Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men.

1 reference

12 December 2020

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial

1 reference

12 December 2020

Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia

1 reference

12 December 2020

Benign prostatic hyperplasia. Practical treatment guidelines

1 reference

12 December 2020

The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride

1 reference

12 December 2020

Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia

1 reference

12 December 2020

Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

The role of dihydrotestosterone in benign prostatic hyperplasia

1 reference

12 December 2020

5alpha-reductase: history and clinical importance

1 reference

12 December 2020

Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer

1 reference

12 December 2020

Comparison of clinical trials with finasteride and dutasteride

1 reference

12 December 2020

Androgens and alopecia

1 reference

12 December 2020

Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia.

1 reference

12 December 2020

Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia

1 reference

12 December 2020

AUA Guidelines and Their Impact on the Management of BPH: An Update

1 reference

12 December 2020

The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia

1 reference

12 December 2020

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

1 reference

12 December 2020

Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers

1 reference

12 December 2020

Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia

1 reference

12 December 2020

Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines

1 reference

12 December 2020

Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor

1 reference

12 December 2020

Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride

1 reference

12 December 2020

alpha1-Adrenoceptor subtype selectivity and lower urinary tract symptoms.

1 reference

12 December 2020

Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

1 reference

12 December 2020

Pharmacological and molecular evidence for the expression of the two steroid 5 alpha-reductase isozymes in normal and hyperplastic human prostatic cells in culture.

1 reference

12 December 2020

The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study

1 reference

12 December 2020

Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer

1 reference

12 December 2020

Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia

1 reference

12 December 2020

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia

1 reference

12 December 2020

Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.

1 reference

12 December 2020

The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate

1 reference

12 December 2020

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor

1 reference

12 December 2020

Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line

1 reference

12 December 2020

The influence of finasteride on the development of prostate cancer

1 reference

12 December 2020

The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge

1 reference

12 December 2020

Quality of Life and Economic Considerations in the Management of Prostate Cancer

1 reference

12 December 2020

Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial

1 reference

12 December 2020

The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).

1 reference

12 December 2020

Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia

1 reference

12 December 2020

Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting.

1 reference

12 December 2020

The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study

1 reference

12 December 2020

Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer

1 reference

12 December 2020

Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.

1 reference

12 December 2020

Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor Dutasteride

1 reference

12 December 2020

Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue

1 reference

12 December 2020

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

12 December 2020

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

12 December 2020

Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: A landmark national US survey

1 reference

12 December 2020

Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia

1 reference

12 December 2020

Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk

1 reference

12 December 2020

5α-Reductase Type 1 Immunostaining is Enhanced in Some Prostate Cancers Compared With Benign Prostatic Hyperplasia Epithelium

1 reference

12 December 2020

Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible

1 reference

12 December 2020

Chemoprevention using dutasteride: the REDUCE trial

1 reference

12 December 2020

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations

1 reference

12 December 2020

Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice.

1 reference

12 December 2020

The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men

1 reference

12 December 2020

Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design

1 reference

12 December 2020

Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia

1 reference

12 December 2020

An assessment of the diagnosed prevalence of diseases in men 50 years of age or older.

1 reference

12 December 2020

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor

1 reference

12 December 2020

Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study

1 reference

12 December 2020

10.2165/00003495-200868040-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1039280559

0 references

1 reference